Coagulation

World Hematology and Coagulation Market Research Report 2023: A Nearly $10 Billion-Dollar Market - Demand for Decentralized Testing, New Technologies and Aging Populations Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 6, 2023
Health, Biotechnology, Platelet, Hematocrit, Stroke, Decentralization, Segment, Enzyme, Ageing, Artery, Cell, Fibrinolysis, Government, Literature, Protein, Bone marrow, PTT, Hemostasis, CBC, Laboratory, Country Markets, Blood, Anemia, IVD, Reticulocyte, Automation, Cryptocurrency, Microscope, Birth control, Renewable energy, Coagulation, Hematology

There is a nearly $10 billion-dollar market for hematology and coagulation IVD testing.

Key Points: 
  • There is a nearly $10 billion-dollar market for hematology and coagulation IVD testing.
  • Increasingly growth is driven by new technologies, the aging population, and the demand for decentralized testing.
  • The basis of hematology testing is the complete blood count (CBC) that provides information on blood components: hemoglobin, hematocrit, red blood cells, white blood cells, reticulocytes, and platelets.
  • The CBC is run as part of the normal work up in an annual health exam and for every inpatient.

eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023

Retrieved on: 
Monday, June 5, 2023
Xenotransplantation, Thrombotic microangiopathy, Tissue, Survivor, TGS, ATI, DNA, Immunology, Serum, Biotechnology, Gene editing, Survival, AMR, Cell, Antibody, Doctor of Philosophy, TG, Research, DSA, Harvard Medical School, Transplant, Chemistry, Sera, Protein, Public, Animal, MD, Plasma, Risk, Coagulation, Filtration, Hospital, ATC, Hokkaido University, SLA, Health, Safety, Pelvic floor dysfunction, Postdoctoral researcher, TMA, Medical device, Dentistry, Vaccine, Dietary supplement, Primate

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress (ATC) 2023, held June 3 – June 7, 2023 in San Diego, CA.

Key Points: 
  • CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress (ATC) 2023, held June 3 – June 7, 2023 in San Diego, CA.
  • “The data we are presenting at ATC 2023 demonstrate eGenesis’ continued leadership in the field of xenotransplantation,” said Mike Curtis, Ph.D., CEO of eGenesis.
  • Oral Presentation: Genetically Modified Porcine Kidneys Expressing Human Transgenes Support >2-year Survival in Porcine Donor to Cynomolgus Macaque Recipient Xenotransplantation.
  • eGenesis scientists genetically engineered porcine donors to remove three known xenoantigens implicated in hyperacute rejection.

Bayer Receives U.S. FDA Fast Track Designation for asundexian Atrial Fibrillation Program

Retrieved on: 
Tuesday, May 16, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Priority review, Bleeding, Therapy, Atrial fibrillation, Stroke, Accelerated approval (FDA), Fast track (FDA), Thrombosis, Anticoagulant, Patient, Risk, Executive Committee, Coagulation, AF, S-1 Executive Committee, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Pharmaceutical industry, Birth control, Bayer, Research

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF).

Key Points: 
  • Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF).
  • This news follows asundexian’s first U.S. FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022.
  • Fast Track Designation is intended to facilitate the development and expedite the review of drug candidates to treat serious medical conditions and fulfill unmet medical needs.
  • “The second Fast Track Designation for asundexian emphasizes the medical need to prevent stroke and systemic embolism in people diagnosed with atrial fibrillation,” said Christian Rommel, Member of the Executive Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development.

Wanhua Chemical Signs Cooperation Deal with French Enterprise to Collaborate on Penglai Industrial Park Seawater Desalination Project

Retrieved on: 
Monday, May 15, 2023
MDI, CREC, China Railway Group Limited, Ultrafiltration, History, Carbon, Wanhua Chemical Group, Belt and Road Initiative, Chemical substance, Seawater, Water, Coagulation, Council, Penglai, Filtration, Belt, Water resources, Natural gas

BEIJING, May 15, 2023 /PRNewswire/ -- Wanhua Chemical ("Wanhua" or "the Company"; 600309.SS), along with other representatives from China and France, signed a three-party cooperative agreement recently to collaborate on Wanhua Chemical's Penglai Industrial Park seawater desalination project.

Key Points: 
  • BEIJING, May 15, 2023 /PRNewswire/ -- Wanhua Chemical ("Wanhua" or "the Company"; 600309.SS), along with other representatives from China and France, signed a three-party cooperative agreement recently to collaborate on Wanhua Chemical's Penglai Industrial Park seawater desalination project.
  • Committed to forging a chemical industrial base that integrates fine chemicals, petrochemicals, and high-end new energy materials, Wanhua's Penglai Industrial Park will be the Company's seventh industrial park globally.
  • Besides, Wanhua Chemical has made a handful of attempts in the comprehensive management of water resources.
  • For more information about Wanhua Chemical and its Penglai Industrial Park seawater desalination project, please visit https://en.whchem.com/ .

Wanhua Chemical Signs Cooperation Deal with French Enterprise to Collaborate on Penglai Industrial Park Seawater Desalination Project

Retrieved on: 
Monday, May 15, 2023
MDI, CREC, China Railway Group Limited, Ultrafiltration, History, Carbon, Wanhua Chemical Group, Belt and Road Initiative, Chemical substance, Seawater, Water, Coagulation, Council, Penglai, Filtration, Belt, Water resources, Natural gas

BEIJING, May 15, 2023 /PRNewswire/ -- Wanhua Chemical ("Wanhua" or "the Company"; 600309.SS), along with other representatives from China and France, signed a three-party cooperative agreement recently to collaborate on Wanhua Chemical's Penglai Industrial Park seawater desalination project.

Key Points: 
  • BEIJING, May 15, 2023 /PRNewswire/ -- Wanhua Chemical ("Wanhua" or "the Company"; 600309.SS), along with other representatives from China and France, signed a three-party cooperative agreement recently to collaborate on Wanhua Chemical's Penglai Industrial Park seawater desalination project.
  • Committed to forging a chemical industrial base that integrates fine chemicals, petrochemicals, and high-end new energy materials, Wanhua's Penglai Industrial Park will be the Company's seventh industrial park globally.
  • Besides, Wanhua Chemical has made a handful of attempts in the comprehensive management of water resources.
  • For more information about Wanhua Chemical and its Penglai Industrial Park seawater desalination project, please visit https://en.whchem.com/ .

 Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease

Retrieved on: 
Monday, May 15, 2023
Neurology, Biotechnology, Pharmaceutical, Optical, Health, Infectious Diseases, Clinical Trials, Other Health, Alzheimer's disease, Marketing, DDF, Business, Janssen, MBA, Retina, Vanderbilt University, Genentech, Eli Lilly, Venture, Forma, Acquisition, Novartis, Fibrin, Patient, Engineering, Coagulation, Novo Nordisk, Growth, Immunology, Therapy, Chemical engineering, Infection, Safety, Roche, Pharmaceutical industry, Cidariini, Ophthalmology

“Initiating first-in-human dosing for THN391 is a significant milestone and we’re excited about the approach that Therini Bio is taking towards treating Alzheimer’s disease and other inflammatory neurodegenerative and retinal diseases.

Key Points: 
  • “Initiating first-in-human dosing for THN391 is a significant milestone and we’re excited about the approach that Therini Bio is taking towards treating Alzheimer’s disease and other inflammatory neurodegenerative and retinal diseases.
  • "We are thrilled to announce the initiation of first-in-human dosing for THN391, our fibrin-targeting therapeutic candidate for Alzheimer's disease.
  • “I look forward to working alongside the Therini Bio team to help advance this candidate and its pipeline of fibrin-targeted therapeutic candidates.
  • We are thrilled to have Frank join Therini Bio as Executive Chairperson of the Board, as Therini Bio advances their fibrin-targeting therapeutic candidate for Alzheimer's disease and retinal diseases.

Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases

Retrieved on: 
Thursday, April 27, 2023
Biotechnology, Health, Seniors, Pharmaceutical, Optical, Neurology, Research, Genetics, Consumer, Science, Clinical Trials, Fillit, BM, DME, Brain, Diabetic retinopathy, NIA, Partner (business rank), Multimedia, Multiple sclerosis, Inflammation, Risk, DSM-IV codes, National Institute on Aging, MS, Eli Lilly, Bangladesh Technical Education Board, Alzheimer's disease, Doctor of Philosophy, Fibrin, Coagulation, Microglia, Entrepreneurship, Merck, Merck & Co., AD, Safety, NIH, Pharmaceutical industry, Vaccine, Retina

Therini Bio , Inc., a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the close of a $36M Series A financing round.

Key Points: 
  • Therini Bio , Inc., a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the close of a $36M Series A financing round.
  • The Series A funding brings the total amount raised since inception to $62M.
  • The new funding will enable Therini Bio to advance its pipeline of fibrin-targeting therapies and advance its lead antibody THN391, that binds the inflammation-driving component of fibrin that is known to activate immune responses in neurodegenerative and ophthalmologic diseases.
  • “This funding will enable us to accelerate the development of our lead antibody program targeting inflammatory fibrin in neurodegenerative and retinal diseases.

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Retrieved on: 
Monday, April 17, 2023
AACR, TNF, ITGB6, Neutrophil, Basophil, CRS, Therapeutic index, Pharmacokinetics, American Association for Cancer Research, Quality of life, IL-6, Head, Toxicity, Prostate, Neck, Lung, IL-2, Cytokine release syndrome, Patient, IL-8, SAN, Coagulation, Neoplasm, Lymphocyte, Research, Therapy, Tumor microenvironment, Vaccine

“TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.

Key Points: 
  • “TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.
  • “However, significant unmet needs remain as both the depth and the durability of response with antibody drug conjugates are typically limited.
  • For more details about the AACR Annual Meeting, please visit:
    The posters will be available on Harpoon’s website following today’s presentations.
  • This spatial control of activation may address on-target tissue damage, hence enabling an expansion of the T cell engager target space.

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First‑in‑Class Antibody Therapy for von Willebrand Disease

Retrieved on: 
Thursday, April 6, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, University of Texas Southwestern Medical Center, University, Protein S, VWD, Vega, CTA, Coagulopathy, Trial of the century, Von Willebrand disease, MD, Patient, Coagulation, Quebec platelet disorder, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

Vega Therapeutics , Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated.

Key Points: 
  • Vega Therapeutics , Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated.
  • The clinical trial program will begin with enrollment of healthy volunteers and expand to include patients with von Willebrand disease (VWD).
  • By promoting thrombin generation through targeting Protein S, VGA039 addresses a fundamental mechanism of clot formation in VWD and, as a subcutaneously self-administered antibody therapy, has potential to transform VWD treatment.
  • Vega plans to enroll the Phase 1 clinical trial for VGA039 at clinical trial sites across the U.S. and other countries.

Latin America Vitro Diagnostic (IVD) Tests Market Research Report 2023: Focus on Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela - ResearchAndMarkets.com

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Science, Health, Research, Syphilis, Blood, Interleukin, Autoimmunity, Hormone, Molecular biology, Market, Other Nationalities rugby league team, Histology, Toxicology, Torch, NAT, POC, Leukemia, CT, Pregnancy, Gram, Microbiology, Medium (website), DSM-IV codes, Infection, Flow cytometry, FDP, NG, HPV, BNP, Blood culture, EBV, Allergy, COVID-19, MRSA, Fibrinogen, Hepatitis, AIDS, Hemostasis, Anemia, CMV, IVD, APTT, Glycated hemoglobin, Lymphoma, TSH, Fecal occult blood, HIV, Control, PCT, Thrombosis, MTB, Fertility, Coagulation, Cardiology, LATAM, Drug, Vaccine, Medical imaging, Ureaplasma, Sepsis, Mycoplasma, Myoglobin

The "The Market for In Vitro Diagnostic (IVD) Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and Other Nations)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Market for In Vitro Diagnostic (IVD) Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and Other Nations)" report has been added to ResearchAndMarkets.com's offering.
  • This market report focuses on the market for reagents and instruments in the most important countries of the region.
  • Brazil and Mexico represent the two largest countries in terms of population, accounting for more than half of LATAM total population.
  • For this reason, these two countries have been the focus of many IVD suppliers in recent years.